Ident. | Authors (with country if any) | Title |
---|
000912 (2017) |
Ira M. Jacobson ; Eric Lawitz ; Edward J. Gane ; Bernard E. Willems ; Peter J. Ruane ; Ronald G. Nahass ; Sergio M. Borgia ; Stephen D. Shafran ; Kimberly A. Workowski ; Brian Pearlman ; Robert H. Hyland ; Luisa M. Stamm ; Evguenia Svarovskaia ; Hadas Dvory-Sobol ; Yanni Zhu ; G Mani Subramanian ; Diana M. Brainard ; John G. Mchutchison ; Norbert Br U ; Thomas Berg ; Kosh Agarwal ; Bal Raj Bhandari ; Mitchell Davis ; Jordan J. Feld ; Gregory J. Dore ; Catherine A M. Stedman ; Alexander J. Thompson ; Tarik Asselah ; Stuart K. Roberts ; Graham R. Foster | Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. |
000A38 (2017) |
Marc Bourlière ; Stuart C. Gordon ; Steven L. Flamm ; Curtis L. Cooper ; Alnoor Ramji ; Myron Tong ; Natarajan Ravendhran ; John M. Vierling ; Tram T. Tran ; Stephen Pianko ; Meena B. Bansal ; Victor De Lédinghen ; Robert H. Hyland ; Luisa M. Stamm ; Hadas Dvory-Sobol ; Evguenia Svarovskaia ; Jie Zhang ; K C Huang ; G Mani Subramanian ; Diana M. Brainard ; John G. Mchutchison ; Elizabeth C. Verna ; Peter Buggisch ; Charles S. Landis ; Ziad H. Younes ; Michael P. Curry ; Simone I. Strasser ; Eugene R. Schiff ; K Rajender Reddy ; Michael P. Manns ; Kris V. Kowdley ; Stefan Zeuzem | Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. |
000D98 (2017) |
Ming Jang Chua ; Megan S J. Arnold ; Weijun Xu ; Julien Lancelot ; Suzanne Lamotte ; Gerald F. Sp Th ; Eric Prina ; Raymond J. Pierce ; David P. Fairlie ; Tina S. Skinner-Adams ; Katherine T. Andrews | Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. |
000E91 (2017) |
Josef S. Smolen ; Joel M. Kremer ; Carol L. Gaich ; Amy M. Delozier ; Douglas E. Schlichting ; Li Xie ; Ivaylo Stoykov ; Terence Rooney ; Paul Bird ; Juan Miguel Sánchez Burs N ; Mark C. Genovese ; Bernard Combe | Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). |
001091 (2017) |
Charlotte Viant ; Sophie Guia ; Robert J. Hennessy ; Jai Rautela ; Kim Pham ; Claire Bernat ; Wilford Goh ; Yuhao Jiao ; Rebecca Delconte ; Michael Roger ; Vanina Simon ; Fernando Souza-Fonseca-Guimaraes ; Stephanie Grabow ; Gabrielle T. Belz ; Benjamin T. Kile ; Andreas Strasser ; Daniel Gray ; Phillip D. Hodgkin ; Bruce Beutler ; Eric Vivier ; Sophie Ugolini ; Nicholas D. Huntington | Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. |
001375 (2017) |
Sanjay Mehta ; Bhagavatula Kutumba Srinivasa Sastry ; Rogério Souza ; Adam Torbicki ; Hossein-Ardeschir Ghofrani ; Richard N. Channick ; Marion Delcroix ; Tomás Pulido ; Gérald Simonneau ; John Wlodarczyk ; Lewis J. Rubin ; Pavel Jansa ; Elke Hunsche ; Nazzareno Galiè ; Loïc Perchenet ; Olivier Sitbon | Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. |
001441 (2016) |
Christina M Lck ; James Ryall ; Laura M. Failla ; Janine L. Coates ; Jean-Marc Pascussi ; Joan K. Heath ; Gregory Stewart ; Frédéric Hollande | The A2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism. |
001892 (2016) |
Paolo A. Ascierto ; Grant A. Mcarthur ; Brigitte Dréno ; Victoria Atkinson ; Gabrielle Liszkay ; Anna Maria Di Giacomo ; Mario Mandalà ; Lev Demidov ; Daniil Stroyakovskiy ; Luc Thomas ; Luis De La Cruz-Merino ; Caroline Dutriaux ; Claus Garbe ; Yibing Yan ; Matthew Wongchenko ; Ilsung Chang ; Jessie J. Hsu ; Daniel O. Koralek ; Isabelle Rooney ; Antoni Ribas ; James Larkin | Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. |
002144 (2016) |
Philipp Harter ; Toby Johnson ; Dominique Berton-Rigaud ; Sang-Yoon Park ; Michael Friedlander ; Josep M. Del Campo ; Muneaki Shimada ; Frédéric Forget ; Mansoor R. Mirza ; Nicoletta Colombo ; Claudio Zamagni ; John K. Chan ; Martin Imhof ; Thomas J. Herzog ; Dearbhaile O'Donnell ; Florian Heitz ; Karen King ; Sandy Stinnett ; Catherine Barrett ; Minesh Jobanputra ; Chun-Fang Xu ; Andreas Du Bois | BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. |
002727 (2015) |
B G Feagan ; W J Sandborn ; G. D'Haens ; S D Lee ; M. Allez ; R N Fedorak ; U. Seidler ; S. Vermeire ; I C Lawrance ; A C Maroney ; C H Jurgensen ; A. Heath ; D J Chang | Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. |
002830 (2015) |
Jean Jacques Grob ; Mayur M. Amonkar ; Boguslawa Karaszewska ; Jacob Schachter ; Reinhard Dummer ; Andrzej Mackiewicz ; Daniil Stroyakovskiy ; Kamil Drucis ; Florent Grange ; Vanna Chiarion-Sileni ; Piotr Rutkowski ; Mikhail Lichinitser ; Evgeny Levchenko ; Pascal Wolter ; Axel Hauschild ; Georgina V. Long ; Paul Nathan ; Antoni Ribas ; Keith Flaherty ; Peng Sun ; Jeffrey J. Legos ; Diane Opatt Mcdowell ; Bijoyesh Mookerjee ; Dirk Schadendorf ; Caroline Robert | Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. |
002B66 (2015) |
Mitchell S. Stark ; Vanessa F. Bonazzi ; Glen M. Boyle ; Jane M. Palmer ; Judith Symmons ; Catherine M. Lanagan ; Christopher W. Schmidt ; Adrian C. Herington ; Robert Ballotti ; Pamela M. Pollock ; Nicholas K. Hayward | miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. |
002D63 (2015) |
Andrew J. Muir ; Fred Poordad ; Jacob Lalezari ; Gregory Everson ; Gregory J. Dore ; Robert Herring ; Aasim Sheikh ; Paul Kwo ; Christophe Hézode ; Paul J. Pockros ; Albert Tran ; Joseph Yozviak ; Nancy Reau ; Alnoor Ramji ; Katherine Stuart ; Alexander J. Thompson ; John Vierling ; Bradley Freilich ; James Cooper ; Wayne Ghesquiere ; Rong Yang ; Fiona Mcphee ; Eric A. Hughes ; E Scott Swenson ; Philip D. Yin | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. |
002D97 (2015) |
Fred Poordad ; William Sievert ; Lindsay Mollison ; Michael Bennett ; Edmund Tse ; Norbert Br U ; James Levin ; Thomas Sepe ; Samuel S. Lee ; Peter Angus ; Brian Conway ; Stanislas Pol ; Nathalie Boyer ; Jean-Pierre Bronowicki ; Ira Jacobson ; Andrew J. Muir ; K Rajender Reddy ; Edward Tam ; Grisell Ortiz-Lasanta ; Victor De Lédinghen ; Mark Sulkowski ; Navdeep Boparai ; Fiona Mcphee ; Eric Hughes ; E Scott Swenson ; Philip D. Yin | Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. |
003121 (2015) |
K Rajender Reddy ; Stefan Zeuzem ; Fabien Zoulim ; Ola Weiland ; Andrzej Horban ; Carol Stanciu ; Federico Guillermo Villamil ; Pietro Andreone ; Jacob George ; Elisabeth Dammers ; Min Fu ; Darryl Kurland ; Oliver Lenz ; Sivi Ouwerkerk-Mahadevan ; Thierry Verbinnen ; Jane Scott ; Wolfgang Jessner | Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. |
003191 (2015) |
Anne Floquet ; Ignace Vergote ; Nicoletta Colombo ; Bent Fiane ; Bradley J. Monk ; Alexander Reinthaller ; Paula Calvert ; Thomas J. Herzog ; Werner Meier ; Jae-Weon Kim ; Josep M. Del Campo ; Michael Friedlander ; Carmela Pisano ; Seiji Isonishi ; Rocco J. Crescenzo ; Catherine Barrett ; Karrie Wang ; Ionel Mitrica ; Andreas Du Bois | Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. |
003296 (2014) |
James Larkin ; Paolo A. Ascierto ; Brigitte Dréno ; Victoria Atkinson ; Gabriella Liszkay ; Michele Maio ; Mario Mandalà ; Lev Demidov ; Daniil Stroyakovskiy ; Luc Thomas ; Luis De La Cruz-Merino ; Caroline Dutriaux ; Claus Garbe ; Mika A. Sovak ; Ilsung Chang ; Nicholas Choong ; Stephen P. Hack ; Grant A. Mcarthur ; Antoni Ribas | Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. |
003298 (2014) |
Rishi Puri ; Steven E. Nissen ; Mingyuan Shao ; Christie M. Ballantyne ; Philip J. Barter ; M John Chapman ; Raimund Erbel ; Peter Libby ; Joel S. Raichlen ; Kiyoko Uno ; Yu Kataoka ; Stephen J. Nicholls | Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. |
003299 (2014) |
Brian Stegman ; Rishi Puri ; Leslie Cho ; Mingyuan Shao ; Christie M. Ballantyne ; Phillip J. Barter ; M John Chapman ; Raimund Erbel ; Peter Libby ; Joel S. Raichlen ; Kiyoko Uno ; Yu Kataoka ; Steven E. Nissen ; Stephen J. Nicholls | High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. |
003357 (2014) |
Michael Manns ; Stanislas Pol ; Ira M. Jacobson ; Patrick Marcellin ; Stuart C. Gordon ; Cheng-Yuan Peng ; Ting-Tsung Chang ; Gregory T. Everson ; Jeong Heo ; Guido Gerken ; Boris Yoffe ; William J. Towner ; Marc Bourliere ; Sophie Metivier ; Chi-Jen Chu ; William Sievert ; Jean-Pierre Bronowicki ; Dominique Thabut ; Youn-Jae Lee ; Jia-Horng Kao ; Fiona Mcphee ; Justin Kopit ; Patricia Mendez ; Misti Linaberry ; Eric Hughes ; Stephanie Noviello | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. |
003385 (2014) |
Rishi Puri ; Steven E. Nissen ; Mingyuan Shao ; Christie M. Ballantyne ; Phillip J. Barter ; M John Chapman ; Raimund Erbel ; Peter Libby ; Joel S. Raichlen ; Kiyoko Uno ; Yu Kataoka ; Stephen J. Nicholls | Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. |